PDGFRB and Chronic Eosinophilic Leukemia, Not Otherwise Specified: Unlike clonal eosinophilic disorders secondary to PDGFRA and PDGFRB translocations [8], the WHO-defined CEL-NOS entity is not responsive to imatinib mesylate monotherapy.